Refractory Non-Hodgkin Lymphoma Clinical Trials in Houston, Texas

4 studies are recruiting for refractory non-hodgkin lymphoma in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

2. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

   This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   36 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT07188558 on ClinicalTrials.gov

3. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

   This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Texas MD Anderson Cancer Center, Houston, Texas

   Locations

   12 in total

   Run by

   Indapta Therapeutics, INC.

   See if you can join NCT06119685 on ClinicalTrials.gov

4. Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

   The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aim…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   3 in total

   Run by

   SIRPant Immunotherapeutics, Inc.

   See if you can join NCT05967416 on ClinicalTrials.gov